ArticleBMC cancer2025
A nomogram for breast cancer brain metastasis patients after stereotactic radiotherapy.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biological aging enhances prognostic stratification beyond chronological age in breast cancer brain metastases.Journal of neuro-oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo evaluate prognostic factors in breast cancer brain metastasis (BCBM) patients receiving stereotactic radiotherapy (SRT) and to develop an effective prediction model for overall survival (OS). PATIENTS AND
methodsWe retrospectively collected clinical and pathological data from BCBM patients treated with SRT. Prognostic factors were assessed using univariate and multivariate Cox regression analyses. A nomogram was developed based on Cox models and validated internally using bootstrap and cross-validation methods. Model discrimination was evaluated through calibration plots and the concordance index (C-index), while clinical utility was assessed using clinical decision curve analysis (DCA).
resultsAmong 101 BCBM patients who received SRT, 96 patients were included in the analysis. Multivariate analysis identified several prognostic factors for OS, including the number of brain metastases (BM), molecular subtypes of breast cancer, BM as the site of first metastasis, Karnofsky Performance Status (KPS), and receiving systemic therapy after SRT. The final model, selected by the Akaike information criterion (AIC), included age, KPS, molecular subtype, number of BM, BM as the site of first metastasis, planning target volume (PTV), liver metastases, albumin levels, and neutrophil count. The calibration curve demonstrated good consistency between the nomogram predictions and actual observations. The C-index for the nomogram was 0.823 (95% CI, 0.760–0.885), and the bias-corrected C-index, generated via bootstrap validation with 1,000 resamples, was 0.772. This performance was significantly better than that of the Recursive partitioning analysis (RPA: C-index: 0.627), the Graded Prognostic Assessment (GPA: C-index: 0.637), and Breast-specific Graded Prognostic Assessment (breast-GPA: C-index: 0.699) systems. Kaplan-Meier survival curves showed excellent discrimination among four groups classified by this nomogram.
conclusionThe proposed nomogram provides more accurate predictions for BCBM patients undergoing SRT, outperforming traditional prognostic models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.